Shares of GlaxoSmithKline plc (NYSE:GSK) gapped up prior to trading on Friday . The stock had previously closed at $38.80, but opened at $39.61. GlaxoSmithKline shares last traded at $40.87, with a volume of 4203748 shares.
Several analysts have commented on the stock. TheStreet raised shares of GlaxoSmithKline from a “c” rating to a “b” rating in a research report on Monday, August 6th. Bank of America set a $40.00 target price on shares of GlaxoSmithKline and gave the stock a “hold” rating in a research report on Wednesday, July 25th. Deutsche Bank reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, August 1st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Friday, July 20th. Finally, Zacks Investment Research raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $41.57.
The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 8.13. The firm has a market capitalization of $98.55 billion, a PE ratio of 14.18, a price-to-earnings-growth ratio of 1.94 and a beta of 0.87.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 11th. Investors of record on Friday, August 10th were issued a dividend of $0.496 per share. This represents a $1.98 annualized dividend and a dividend yield of 4.85%. The ex-dividend date of this dividend was Thursday, August 9th. GlaxoSmithKline’s dividend payout ratio is currently 68.06%.
In other news, insider Plc Glaxosmithkline acquired 148,818 shares of the firm’s stock in a transaction that occurred on Monday, July 30th. The stock was acquired at an average cost of $11.00 per share, with a total value of $1,636,998.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. Optimum Investment Advisors boosted its holdings in GlaxoSmithKline by 88.5% in the 3rd quarter. Optimum Investment Advisors now owns 2,749 shares of the pharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,291 shares during the period. Kiley Juergens Wealth Management LLC bought a new stake in GlaxoSmithKline in the 2nd quarter valued at $113,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in GlaxoSmithKline in the 2nd quarter valued at $134,000. Private Capital Group LLC boosted its holdings in GlaxoSmithKline by 1,904.6% in the 1st quarter. Private Capital Group LLC now owns 3,889 shares of the pharmaceutical company’s stock valued at $154,000 after purchasing an additional 3,695 shares during the period. Finally, Toronto Dominion Bank boosted its holdings in GlaxoSmithKline by 46.0% in the 2nd quarter. Toronto Dominion Bank now owns 4,600 shares of the pharmaceutical company’s stock valued at $186,000 after purchasing an additional 1,450 shares during the period. 11.00% of the stock is owned by hedge funds and other institutional investors.
GlaxoSmithKline Company Profile (NYSE:GSK)
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.